MEDICARBONE PATENTED TECHNOLOGY
A new, minimally invasive approach to intramedullary nailing
MediCarbone’s intramedullary fixation device consists of three components:
- A carbon fiber-reinforced IM sleeve that conforms to the intramedullary cavity
- An injectable and rapid-cure polymeric resin system
- AI technology to enable tunable, patient-specific properties for better outcomes.
Together, these elements form a game-changing treatment alternative for fracture fixation of long bones or pre-strengthening of weak long bones (to avoid future fractures).
The intramedullary sleeve is a two-layered system with openings that enable resin injection and the transmission of light through a diffusive light guide for photocuring the resin. The inner porous carbon fabric layer acts as a reinforcement and can compress or stretch to conform to the cavity; the outer non-porous polymer layer conforms to the reamed cavity after it is injected with photocure resin, while preventing resin leakage into the medullary cavity. This unique IM sleeve design eliminates the need for additional hardware for fracture stabilization and allows for the incorporation of drugs and biologics.
The MediCarbone system includes a photocurable resin which contains formulated functional materials adapted to photocure into a solid polymer. The resin comes pre-packaged in amber syringes ready for injection.
After injection the sleeve will conform to the cavity and a light source is activated and resin is cured to form the MediCarbone IM device inside the bone. Photocuring is achieved within 10 minutes after the light is applied. The polymer chemistry is specifically designed to enable minimally invasive removal once the bone has healed and maintains radiopacity during surgical and postsurgical imaging.
The MediCarbone artificial intelligence (AI) tool aims to solve the technical problem of determining an optimal, minimally invasive way to treat bone fractures. The system is capable of accepting patient-specific data and outputting the optimal size, shape and materials of the composite device that will most effectively treat that specific patient’s bone fracture.
Be on The Front Lines of a Fracture Treatment Revolution.
MediCarbone uses FDA-cleared polymer components, and the device is moving rapidly toward clinical trials. North American Science Associates (NAMSA)—the world’s only 100% medical device-focused, full continuum Contract Research Organization (CRO)—will provide guidance on the regulatory pathway, evidence requirements, and pre-clinical and clinical testing plans to help MediCarbone towards FDA regulatory submissions. Learn how you can get involved now—and take advantage of a IM market that is expected to reach $1.2B by 2030.